Marguerite Nader - Ventas Independent Director
| VTR Stock | USD 66.85 0.86 1.27% |
Insider
Marguerite Nader is Independent Director of Ventas Inc since 2020.
| Age | 52 |
| Tenure | 5 years |
| Phone | 877 483 6827 |
| Web | https://www.ventasreit.com |
Marguerite Nader Latest Insider Activity
Tracking and analyzing the buying and selling activities of Marguerite Nader against Ventas stock is an integral part of due diligence when investing in Ventas. Marguerite Nader insider activity provides valuable insight into whether Ventas is net buyers or sellers over its current business cycle. Note, Ventas insiders must abide by specific rules, including filing SEC forms every time they buy or sell Ventas'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Marguerite Nader over a month ago Disposition of 9691 shares by Marguerite Nader of Equity Lifestyle subject to Rule 16b-3 | ||
Marguerite Nader over a month ago Disposition of 4442 shares by Marguerite Nader of Equity Lifestyle subject to Rule 16b-3 | ||
Marguerite Nader over six months ago Disposition of 33000 shares by Marguerite Nader of Equity Lifestyle at 75.52 subject to Rule 16b-3 | ||
Marguerite Nader over six months ago Disposition of 1587 shares by Marguerite Nader of Equity Lifestyle at 66.88 subject to Rule 16b-3 |
Ventas Management Efficiency
The company has Return on Asset of 0.018 % which means that on every $100 spent on assets, it made $0.018 of profit. This is way below average. Ventas' management efficiency ratios could be used to measure how well Ventas manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Billy Rainey | Healthcare Realty Trust | N/A | |
| Michele Reber | Omega Healthcare Investors | N/A | |
| Lisa EgbuonuDavis | Omega Healthcare Investors | N/A | |
| Lori Wittman | Global Medical REIT | 62 | |
| Julie Wilson | Healthcare Realty Trust | 52 | |
| Ajay Gupta | Healthcare Realty Trust | 43 | |
| Amy Hall | Healthpeak Properties | 41 | |
| Jingguo Zhang | Global Medical REIT | 55 | |
| Tim Staggs | Healthcare Realty Trust | N/A | |
| David Travis | National Health Investors | 50 | |
| Mary Jensen | Global Medical REIT | N/A | |
| Eric Gillis | CareTrust REIT | N/A | |
| Gail Makode | Omega Healthcare Investors | 49 | |
| Thomas Thompson | Healthpeak Properties | 79 | |
| James Kilroy | Healthcare Realty Trust | 48 | |
| Michael Costa | Sabra Healthcare REIT | 45 | |
| Taylor CPA | Omega Healthcare Investors | 63 | |
| W Dukes | Healthpeak Properties | 58 | |
| Jamie Barber | Global Medical REIT | 47 | |
| Robert CPA | Global Medical REIT | 59 | |
| Neal Ballew | Omega Healthcare Investors | 39 | |
Management Performance
| Return On Equity | 0.0084 | ||||
| Return On Asset | 0.018 |
Ventas Inc Leadership Team
Elected by the shareholders, the Ventas' board of directors comprises two types of representatives: Ventas inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ventas. The board's role is to monitor Ventas' management team and ensure that shareholders' interests are well served. Ventas' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ventas' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edmund III, Chief VP | ||
| Carey JD, General VP | ||
| Jay Gellert, Independent Director | ||
| Richard JD, Senior Advisor | ||
| Maurice Smith, Independent Director | ||
| Richard Gilchrist, Independent Director | ||
| Louise Adhikari, VP Communications | ||
| Robert Probst, Chief Financial Officer, Executive Vice President | ||
| J Hutchens, Executive Vice President - Senior Housing | ||
| Roxanne Martino, Independent Director | ||
| Justin Hutchens, Executive Officer | ||
| Randy Sohanaki, Vice President - IT Applications | ||
| Julie Robinson, Senior Investments | ||
| Brian Wood, Chief VP | ||
| John Cobb, Executive Vice President, Chief Investment Officer | ||
| Peter Bulgarelli, Executive Vice President and President and Chief Executive Officer, Lillibridge Healthcare Services, Inc. | ||
| Bhavana Devulapally, Senior Vice President, Chief Information Officer | ||
| Michael Embler, Independent Director | ||
| Walter Rakowich, Independent Director | ||
| Debra Cafaro, Chairman of the Board, Chief Executive Officer | ||
| Gregory Liebbe, Senior Vice President Chief Accounting Officer, Controller | ||
| Robert Reed, Independent Director | ||
| Timothy Sanders, Senior Investment Officer | ||
| Christian Cummings, Senior Housing | ||
| Melody Barnes, Independent Director | ||
| James Shelton, Presiding Independent Director | ||
| Matthew Lustig, Independent Director | ||
| Sean Nolan, Independent Director | ||
| Carey Roberts, Executive Vice President General Counsel and Ethics & Compliance Officer | ||
| Marguerite Nader, Independent Director |
Ventas Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ventas a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0084 | ||||
| Return On Asset | 0.018 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.16 % | ||||
| Current Valuation | 42.44 B | ||||
| Shares Outstanding | 437.14 M | ||||
| Shares Owned By Insiders | 0.56 % | ||||
| Shares Owned By Institutions | 99.91 % | ||||
| Number Of Shares Shorted | 12.45 M | ||||
| Price To Earning | 909.80 X |
Additional Tools for Ventas Stock Analysis
When running Ventas' price analysis, check to measure Ventas' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ventas is operating at the current time. Most of Ventas' value examination focuses on studying past and present price action to predict the probability of Ventas' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ventas' price. Additionally, you may evaluate how the addition of Ventas to your portfolios can decrease your overall portfolio volatility.